In this video interview, Kimberly Tableman, founder & CEO, ESPERO, discusses how EDC and EHR data can be streamlined to increase efficiency at sites.
In a recent video interview with Applied Clinical Trials, Kimberly Tableman, founder & CEO, ESPERO, discussed the challenges and trends in protocol development for clinical trials. She also highlighted technological advancements, such as data interoperability standards like ICH M11 and CDISC, and how they are expected to streamline protocol development and support generative AI in 2025.
ACT: What do you think should be top of mind for clinical operations executives going in 2025?
Tableman: I also think we're seeing a lot with real-world evidence and real-world data. Overall, there's an opportunity for streamlining again, at the site. Eighty percent of the data that we collect in the EDC is also collected in the EHR, and we're seeing a lot of solutions from a tech perspective out there, where you actually can leverage the data that's being input into the EHR, leverage that into the EDC, and then there's only about 20% of the data that's very specific to clinical research that then has to be filled out. That's a huge benefit to the site, because we talk a lot about burden for the site, and removing that burden, making life easier for them, not asking them to dual data enter the same information is really a huge benefit.
